A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
- PMID: 33928108
- PMCID: PMC8076523
- DOI: 10.3389/fmed.2021.655871
A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
Abstract
Obesity is one of the epidemics of our era. Its prevalence is higher than 30% in the U.S. and it is estimated to increase by 50% in 2030. Obesity is associated with a higher risk of all-cause mortality and it is known to be a cause of chronic kidney disease (CKD). Typically, obesity-related glomerulopathy (ORG) is ascribed to renal hemodynamic changes that lead to hyperfiltration, albuminuria and, finally, impairment in glomerular filtration rate due to glomerulosclerosis. Though not only hemodynamics are responsible for ORG: adipokines could cause local effects on mesangial and tubular cells and podocytes promoting maladaptive responses to hyperfiltration. Furthermore, hypertension and type 2 diabetes mellitus, two conditions generally associated with obesity, are both amplifiers of obesity injury in the renal parenchyma, as well as complications of overweight. As in the native kidney, obesity is also related to worse outcomes in kidney transplantation. Despite its impact in CKD and cardiovascular morbility and mortality, therapeutic strategies to fight against obesity-related CKD were limited for decades to renin-angiotensin blockade and bariatric surgery for patients who accomplished very restrictive criteria. Last years, different drugs have been approved or are under study for the treatment of obesity. Glucagon-like peptide-1 receptor agonists are promising in obesity-related CKD since they have shown benefits in terms of losing weight in obese patients, as well as preventing the onset of macroalbuminuria and slowing the decline of eGFR in type 2 diabetes. These new families of glucose-lowering drugs are a new frontier to be crossed by nephrologists to stop obesity-related CKD progression.
Keywords: adiposity; chronic kidney disease; insulin resistance; kidney transplantation; obesity.
Copyright © 2021 García-Carro, Vergara, Bermejo, Azancot, Sellarés and Soler.
Conflict of interest statement
AV reports non-financial support from Mundipharma, outside the submitted work. MS reports personal fees from NovoNordisk, Janssen, AstraZeneca, Fresenius, Mundipharma, Pfizer, Bayer and Vifor, grants and non-financial support from Boehringer, and non-financial support from Eli Lilly and Esteve outside of the submitted work. CG-C has received travel and congress fees support from Astra-Zeneca, Esteve, NovoNordisk, Boehringer-Ingelheim Lilly, Astellas, Otsuka, Novartis and Baxter. CG-C has given scientific lectures and participated in advisory boards organized by Astra-Zeneca, Boehringer-Ingelheim Lilly, Mundipharma and NovoNordisk. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8076523/bin/fmed-08-655871-g0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8076523/bin/fmed-08-655871-g0002.gif)
Similar articles
-
Obesity-Related Chronic Kidney Disease: Principal Mechanisms and New Approaches in Nutritional Management.Front Nutr. 2022 Jun 24;9:925619. doi: 10.3389/fnut.2022.925619. eCollection 2022. Front Nutr. 2022. PMID: 35811945 Free PMC article. Review.
-
Obesity Management and Chronic Kidney Disease.Semin Nephrol. 2021 Jul;41(4):392-402. doi: 10.1016/j.semnephrol.2021.06.010. Semin Nephrol. 2021. PMID: 34715968 Review.
-
Obesity-Related Glomerulopathy: Clinical Management.Semin Nephrol. 2021 Jul;41(4):358-370. doi: 10.1016/j.semnephrol.2021.06.007. Semin Nephrol. 2021. PMID: 34715965 Review.
-
Nutrition and Obesity Impacts on Kidney Health.Contrib Nephrol. 2021;199:24-42. doi: 10.1159/000517669. Epub 2021 Aug 3. Contrib Nephrol. 2021. PMID: 34343991 Review.
-
The kidney and cardiovascular outcome trials.J Diabetes. 2018 Feb;10(2):88-89. doi: 10.1111/1753-0407.12616. J Diabetes. 2018. PMID: 29031006
Cited by
-
Framework of Guidelines for Management of CKD in Asia.Kidney Int Rep. 2023 Dec 22;9(4):752-790. doi: 10.1016/j.ekir.2023.12.010. eCollection 2024 Apr. Kidney Int Rep. 2023. PMID: 38765566 Free PMC article. No abstract available.
-
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).J Clin Transl Endocrinol. 2024 Apr 2;36:100341. doi: 10.1016/j.jcte.2024.100341. eCollection 2024 Jun. J Clin Transl Endocrinol. 2024. PMID: 38616864 Free PMC article. Review.
-
Relevance of obesity-related organ damage and metabolic syndrome classification in cardiovascular and renal risk stratification in patients with essential hypertension.Front Cardiovasc Med. 2024 Mar 28;11:1369090. doi: 10.3389/fcvm.2024.1369090. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38606379 Free PMC article.
-
Non-linear relationship between body roundness index and albuminuria among children and adolescents aged 8-19 years: A cross-sectional study.PLoS One. 2024 Mar 7;19(3):e0299509. doi: 10.1371/journal.pone.0299509. eCollection 2024. PLoS One. 2024. PMID: 38451930 Free PMC article.
-
Sleeve gastrectomy and one-year outcomes: Impact on cardiovascular, renal and metabolic parameters.Surg Open Sci. 2024 Jan 12;17:65-69. doi: 10.1016/j.sopen.2024.01.004. eCollection 2024 Jan. Surg Open Sci. 2024. PMID: 38298437 Free PMC article.
References
-
- Obesity: Preventing and Managing the Global Epidemic. Geneva: World Health Organization—Google Libros. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous